Image pharmaphorum Editor Views & Analysis To unlock innovation, pharma needs to be honest about failur... Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock inn News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease. Views & Analysis Patient centricity makes ethical and commercial sense Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense. Views & Analysis Disease spotlight: Duchenne muscular dystrophy (DMD) Load more results
Views & Analysis To unlock innovation, pharma needs to be honest about failur... Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock inn
News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.
Views & Analysis Patient centricity makes ethical and commercial sense Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.